The US Association for Accessible Medicines says it is actively working to mitigate coronavirus-related disruptions on the off-patent industry’s supply chain, with contingency planning a “top priority” for generics and biosimilars firms.
“AAM is working closely with all stakeholders, including the US government, to mitigate disruptions to patient access,” the industry association...





